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REVIEW
PROTACs– a game-changing technology
Markella Konstantinidoua, Jingyao Lia, Bidong Zhanga, Zefeng Wanga, Shabnam Shaabania, Frans Ter Brakea,
Khaled Essaa and Alexander Dömlinga
aDrug Design, University of Groningen, Groningen, The Netherlands
ABSTRACT
Introduction: Proteolysis – targeting chimeras (PROTACs) have emerged as a new modality with the
potential to revolutionize drug discovery. PROTACs are heterobifunctional molecules comprising of
a ligand targeting a protein of interest, a ligand targeting an E3 ligase and a connecting linker. The aim
is instead of inhibiting the target to induce its proteasomal degradation.
Areas covered: PROTACs, due to their bifunctional design, possess properties that differentiate them
from classical inhibitors. A structural analysis, based on published crystal aspects, kinetic features and
aspects of selectivity are discussed. Specific types such as homoPROTACs, PROTACs targeting Tau
protein and the first PROTACs recently entering clinical trials are examined.
Expert opinion: PROTACs have shown remarkable biological responses in challenging targets, includ-
ing an unprecedented selectivity over protein family members and even efficacy starting from weak or
unspecific binders. Moreover, PROTACs are standing out from classical pharmacology by inducing the
degradation of the target protein and not merely its inhibition. However, there are also challenges in
the field, such as the rational structure optimization, the evolution of computational tools, limited
structural data and the greatly anticipated clinical data. Despite the remaining hurdles, PROTACs are
expected to soon become a new therapeutic category of drugs.
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Proteolysis-targeting chimeras (PROTACs) were first reported
in 2001 [1] as chimeric molecules that artificially target the
ubiquitin ligase complex, Skp1-Cullin-F box. In the beginning,
PROTACs were considered merely an academic exercise or as
Craig Crews stated a ‘cute chemical curiosity’ [2]. Nowadays,
almost two decades later, PROTACs are recognized as a new
modality in drug discovery and have the potential to become
the new blockbuster therapeutics [2].
PROTACs are bifunctional molecules that hijack the ubiquitin
proteasome system (UPS) in order to achieve the degradation of
a disease-related target protein. The UPS and the autophagy/
lysosomal routes are the main pathways for the degradation of
intracellular proteins and the maintenance of homeostasis. The
proteasome recognizes proteins that are tagged with ubiquitin,
a small 76 amino acid residue protein, which is highly conserved
among all eukaryotes. Protein ubiquitination is an ATP-
dependent enzymatic reaction that comprises three steps with
three enzyme classes: ubiquitin-activating enzymes (E1
enzymes), ubiquitin-conjugating enzymes (E2 enzymes) and ubi-
quitin ligases (E3 enzymes). First, a ubiquitin molecule is acti-
vated by an E1 enzyme in an ATP-dependent manner. Then, the
activated ubiquitin is transferred to an E2 enzyme and finally, an
E3 ligase catalyzes the transfer of the ubiquitin molecule from E2
to a lysine residue on the substrate via the formation of
a covalent bond [3]. Appropriately ubiquitin-tagged proteins
are recognized by the 26S proteasome and are destroyed by
proteolysis. The discovery of the uttermost importance of the
ubiquitin-proteaseome homeostasis systemwas recognizedwith
the Nobel Prize in Chemistry in 2004 to Aaron Ciechanover,
Avram Hershko, and Irwin Rose.
1.1. Mode of action and unique features
PROTACs are bifunctional molecules consisting of a ligand that
binds to an E3 ligase, connected by a linker to another ligand
that binds to the protein of interest (POI). The rationale behind
this design is that by bringing the E3 ligase in the vicinity of
the protein of interest, ubiquitination by the E3 ligase and
subsequent proteasomal degradation will be triggered.
Interestingly, PROTACs trigger an artificially induced target
degradation, by bringing into close proximity two proteins
that normally would not interact. Thus, the successful interac-
tion relies on the bridging molecule and the adequate affinity
of the PROTAC toward both the E3 ligase and the POI [4]. In
contrast to classical drug pharmacology, no functional activity
is necessary for degrading the POI.
The mode of action of PROTACs is considerably changing the
paradigm of ‘druggable’ targets. The druggability of a target
protein is usually dependent on the inhibition of its activity by
designing small molecules that can bind to a cavity or pocket,
leading to therapeutic benefit [5]. To date, thousands of protein–
protein interactions (PPIs) are known, without deep pockets, with
the absence of well-defined binding sites and with flat protein
interfaces and thus remain challenging targets for small mole-
cules [6]. PROTACs, on the other hand, have been shown to be
CONTACT Alexander Dömling a.s.s.domling@rug.nl Drug Design, University of Groningen, A. Deusinglaan 1, Groningen AV 9713, The Netherlands
EXPERT OPINION ON DRUG DISCOVERY
2019, VOL. 14, NO. 12, 1255–1268
https://doi.org/10.1080/17460441.2019.1659242
© 2019 University Groningen. Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
suitable for targeting transcription factors that lack an active
binding site [7] or for membrane – bound proteins [8].
Regarding their mode of action, in the case of PROTACs, it is
event-driven, rather than occupancy-driven [4]. Occupancy-
driven modalities are a hallmark of classical receptor pharmacol-
ogy and require high drug concentrations in order to maintain
a level of target occupancy that provides sufficient clinical ben-
efit. However, high drug concentrations are also linked to off-
target effects, which can be reduced by drugs with high specifi-
city and favorable pharmacokinetic properties. Conversely,
PROTACs show a catalytic behavior in their ability to induce
proteasomal degradation at substoichiometric levels [9]. Their
efficacy is not limited by equilibrium occupancy. It has been
shown by Crews et al. [9] that a reduction in protein levels of
more than 90% can be reached at nanomolar concentrations,
hitherto impossible to achieve with the occupancy-driven mod-
ality. Moreover, in a recent study of PROTAC-mediated degrada-
tion of receptor tyrosine kinases (RTK) [8], further advantages of
degradation over protein inhibition were demonstrated, includ-
ing a more sustained reduction in downstream signaling and the
maintenance of response duration even after washout of the
PROTAC. The long-lasting biological effect and differential down-
stream signaling of PROTACs represent significant advantages
over classical high receptor occupancy dependent drugs.
PROTACs are not consistent with Lipinski’s rule of five, which is
a significant indication for cell permeability of small molecules.
Although they have relatively large molecular mass, PROTACs can
sustain sufficient intracellular concentrations, which in combina-
tion with the catalytic mechanism of action, is successfully leading
to protein degradation. The exact mechanism of cellular uptake is
not fully understood, but the fact that diverse PROTACs chemo-
types are showing cell penetration in different cell types is an
indication of a passive process [10]. Next, Sun et al. [11] have
systematically investigated the potential usage of PROTACs in
mice and pigs and rhesus monkeys. They observed that the
PROTAC approach could markedly reduce the concentration of
the POIs FKBP12 and BTK in vivo . For example, PROTAC-mediated
depletion of FKBP12 by oral administration occurred in all organs
or tissues except the brain, with a constant effect for about 1 week
after a single treatment. These findings suggest the efficiency and
reversible potential of PROTAC approach in animals and provide
a robust basis for future clinical trials in human patients.
1.2. Types of degraders: cereblon, VHL, MDM2, cIAP1,
other degraders
In the proteasome-mediated protein degradation process, the
E3 ligases are critical components. In humans, more than 600
E3 ligases are known, but to date only a handful of them have
been utilized in PROTACs. PROTACs can be classified according
to the E3 ligases used, which most commonly are cereblon,
Von Hippel Lindau (VHL), mouse double minute 2 homolog
(MDM2), cellular inhibitor of apoptosis protein 1 (cIAP1) and
other degraders (Figure 1).
1.2.1. Cereblon (CRBN)-based degraders
In 2010, Ito et al. [12] revealed that the molecular target and the
primary cause of the teratogenic activity of thalidomide,
a commonly prescribed sedative in pregnant women in the
1950s, was the protein cereblon (CRBN). Thalidomide (1) and
its derivatives lenalidomide (2) and pomalidomide (3) are char-
acterized as immunomodulatory drugs (IMiDs) and have
received approvals for multiple myeloma. Mechanistically,
IMiDs target the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN
[13], which is also known as CRL4CRBN . The binding of IMiDs to
cereblon allows for the recruitment of the transcription factors of
the IKAROS family (IKZF1 and IKZF3) and their ubiquitination
over the endogenous cereblon substrate. In 2014, the crystal
structures of DDB1-CRBN complexes bound to thalidomide [14]
and lenalidomide [15] were solved. Since then, PROTACs with
IMiD small molecules targeting CRBN and diverse proteins of
interest, including the bromodomain and extra-Terminal (BET)
proteins (BRD2/3/4) [16–18], FKBP12 [16], BCR-ABL [19], BRD9
[20], Sirt2 [21], CDK9 [22,23], FLT3 [24], BTK [24,25], ALK [26],
CDK4/CDK6 [27,28] and HDAC6 [29] have been reported.
1.2.2. Von Hippel–Lindau (VHL)-based degraders
Reports for peptide-based PROTACs targeting the Von Hippel
Lindau (VHL) E3 ligase were already described in 2004 [30]. These
early, peptide-based PROTACs were constructed on a peptide
sequence, deriving from the transcription factor hypoxia-
inducible factor 1α (HIF-1α) and thus had the ability to bind to
VHL. The presence of a poly-D-arginine tag assisted in cell
penetration. Later on, considerable effort resulted in the discov-
ery of small-molecule inhibitors targeting the interaction
between HIF-1α and VHL [31–33]. For the highly potent small
molecule inhibitors, X-ray structures elucidated the binding
mode. Furthermore, regarding VHL-PROTACs, the initial – HIF1-
α-derived-peptide was replaced with small molecules bearing
the hydroxyproline moiety (4), thus leading to high-affinity and
high-specificity binders for the VHL. VHL-PROTACs, based on
small molecules in this study, resulted in the effective degrada-
tion of estrogen-related receptor (ERRα) and the kinase RIPK2 [9].
Examples of small molecule-based VHL-PROTACs have shown
effective degradation of HaloTag fusion proteins [34], oncogenic
BCR-ABL [19], BRD4 [35,36], TBK1 [37], several transmembrane
tyrosine kinases (EGFR, HER2, and c-Met) [8] and TRIM24 [38].
1.2.3. MDM2-based degraders
PROTACs based on MDM2, the major E3 ligase targeting the
tumor suppressor p53, are also reported, although there are
considerably fewer reports compared to CRBN and VHL.
Article highlights
● PROTACs with different degraders have shown impressive biological
responses.
● The first crystal structures of ternary complexes show plasticity and
the great impact of the linker in bringing the two proteins in close
proximity.
● The stability of a ternary complex is more significant than the high
affinity of the ligand.
● HomoPROTACs are expected to be valuable probes for investigating
biological functions and substrates of the E3 ligases.
● PET ligands, such as in the case of Tau protein, can also be utilized in
highly effective PROTACs.
● PROTACs for androgen and estrogen receptor are the first ones to
reach clinical trials.
This box summarizes key points contained in the article.
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Nutlins, which are ligands that bind to the p53-binding pocket
of MDM2, are used in the construction of these PROTACs and
disrupt the interaction of MDM2 with the transcription factor
p53, without affecting the E3 ligase activity of MDM2 [39]. In
2008, Crews et al. synthesized PROTACs bearing nutlins (5), as
the MDM2 ligands and the non-steroidal androgen receptor
ligand (SARM) [40]. The cell-permeable PROTAC, successfully
recruited the androgen receptor to MDM2, which as the E3
ligase triggered its ubiquitination and proteasomal degrada-
tion. Moreover, Crews et al. [41] showed that A1874, an
MDM2-recruiting, BRD4 degrading PROTAC, which consists of
idasanutlin (6) as MDM2 ligand and JQ1 as BRD4/BET inhibitor,
was able to degrade the target protein by 98% with nanomo-
lar potency. It is noteworthy that this is the first report of
synergistic antiproliferative effect deriving from the E3 ligase
ligand and the targeting warhead, since the PROTAC was able
both to degrade BRD4 and at the same time stabilize p53.
1.2.4. cIAP1-based degraders
The cellular inhibitor of apoptosis protein 1 (cIAP1) has also been
utilized in PROTAC design. In 2010, Hashimoto’s group [42] dis-
closed fully chemical PROTACs consisting of methyl bestatin
(MeBS) (7), which selectively binds to the BIR3 domain of cIAP1,
the RINGdomain ofwhich promotes auto-ubiquitination, and all-
trans retinoic acid (ATRA), which is the endogenous ligand of
retinoic acid receptors and can recruit the intracellular retinoic-
acid binding proteins CRABP-1 and CRABP-2. The cIAP1-based
PROTAC successfully induced the proteasomal degradation of
the target proteins CRABP-1 and CRABP-2. Further improved
PROTACs were reported [43], by replacing the MeBS moiety
with the MV1 moiety (8), which is a cIAP1/cIAP2/XIAP pan-
ligand and in this case, the PROTAC achieved the double protein
knockdown of cIAP1and CRABP-2. Other examples of protein
degradation utilizing hybrid small molecules named SNIPER
(Specific and Non-genetic IAP-dependent Protein Eraser) have
been reported for estrogen receptor alpha (ERα) [44,45], TACC3
[46] and BCR-ABL [47]. These SNIPERs were bestatin-based but
the use of an improved high-affinity IAP ligand (9) that prefer-
entially recruits X-linked IAP (XIAP) rather than cellular IAP1 led
recently to potent SNIPERs against ERα, BCL-ABL, BRD4, and
phosphodiesterase-4 (PDE4) [48]. Furthermore, effective degra-
dation of the androgen receptor was also demonstrated [49].
1.2.5. Other degraders
The discovery of novel degrons (degradation – inducing inhibi-
tors) is crucial for expanding the PROTAC toolbox. In 2012,
Hedstrom et al. [50] showed that the tert-butyl carbamate-
protected arginine (Boc3Arg) moiety can induce the degradation
of ligands linked to it and remarkably it was proven that the
process was ATP- and ubiquitin-independent. The degradation
of glutathione-S-transferase was achieved by linking Boc3Arg
with the covalent inactivators ethacrynic acid and thiobenzofur-
azan, whereas dihydrofolatereductase was degraded by linking















































































































Figure 1. Structures of E3 ligase degraders.
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cases, degradation is occurring via the 20S proteasome, however
ATP is not necessary and the ubiquitin pathways are not involved
[51]. The authors show that the Boc3Arg-linked ligands are loca-
lizing target proteins to the 20S proteasome and thus induce
degradation. In 2018, Sharma et al. [52] revealed novel scaffolds
that act as selective estrogen-receptor degraders (SERDs) and
show ER antagonistic properties. Three distinct degron classes
were reported with nanomolar potency as ERα degraders and
inhibition of ER target gene expression; lipophilic amino acids
(Leu, Phe, and Trp) (10), bridged bi- and tri-cyclic systems (11)
and monocyclic systems (12).
2. Structural analysis
The crucial step in the mechanism of action for PROTACs is the
formation of a high affinity, long-lasting ternary complex of an E3
ligase – PROTAC – protein of interest. Until recently there was
a lack of structural data for ternary complexes. In 2015, a crystal
structure was reported for a PROTAC bound to one protein of
interest in a binary complex [16]. The high-resolution structure
showed that the PROTAC dBET1(13)was bound to BRD4, proving
similar recognition to the inhibitor JQ1 (14) (PDB 4ZC9) (Figure 2).
In 2017, Ciulli et al. [53] solved the first crystal structure of
a ternary complex with 2.7Å resolution (PDB 5T35). The
PROTAC molecule MZ1 (15) is comprised of the pan-BET
bromodomain inhibitor JQ1 (14) with the potent and specific
VHL ligand VH032 (4) and a three-unit PEG linker. MZ1 is
bound to the second bromodomain of Brd4 (Brd4BD2) and
pVHL:ElonginC:ElonginB and is inducing extensive new hydro-
phobic and electrostatic protein – protein interactions and
protein – ligand contacts (Figure 3), while maintaining the
individual interactions of the respective ligands with the E3
ligase and the bromodomain; the ligand JQ1 binds in the
acetyllysine binding pocket of Brd4BD2, whereas VH032 binds
Figure 2. (a) structures of dBET1 PROTAC (13), JQ1 (14) (BET inhibitor), MZ1 PROTAC (15), VH032 (4) (VHL inhibitor), dBET23 PROTAC (16), dBET6 PROTAC (17) and
ACBI1 PROTAC (18), (b)Binary complex of dBET1 (purple sticks) with BRD4 (blue surface) [PDB 4ZC9], C1)Ternary complex of MZ1 (magenta sticks) with BRD4 (blue
surface), pVHL (green surface), elongin C (red surface), elongin B (gold surface) [PDB 5T35], C2)closeup view BRD4 (blue surface) – MZ1 (magenta sticks) – pVHL
(green surface), D1)Ternary complex of dBET23 (green sticks) with BRD4 (blue surface) and CRBN (magenta surface) [PDB 6BN7], D2) Ternary complex of dBET6
(purple sticks) with BRD4 (blue surface) and CRBN (red surface) [PDB 6BOY].The figure was prepared in Pymol (The PyMOLMolecular graphics system, version 2.0
Schrödinger, LLC).
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to the hydroxyproline binding site of VHL. The PEG linker
forms additional protein – ligand interactions, including van
der Waals interactions and a hydrogen bond. Moreover, sol-
vent-exposed areas of the JQ1 and VH032 ligands are buried
in the interface, as the two proteins come in close proximity.
In total, the extended buried surface area of the ternary com-
plex reaches 2,621 Å2, from which 1,933 Å2 refers to the sur-
face buried by the folding of the ligand. The burial of
extensive surface areas and the formation of new PPIs are
leading to stability of the ternary complex and converts a non-
selective pan-BET inhibitor to a selective degrader.
In 2018, Nowak et al. [54] solved multiple X-ray structures of
degrader – bound CRL4CRBN – BRD4 complexes and showed that
the bound degrader has a unique effect on distinct binding
conformations. The degraders consist of the E3-moiety thalido-
mide (1) that binds to CRL4CRBN, the ligand JQ1 (14) that binds to
BRD4BD1 and BRD4BD2 with equal affinities and flexible linkers of
varying length and composition. In the obtained X-ray structures
of PROTACs dBET23 (16) and dBET6 (17), the linker length and
the linkage position resulted in distinct binding conformations in
the ternary complex. The observed plasticity in the degrader
binding in the same protein (BRD4BD1) provides evidence for
the selectivity profiles among the set of degraders that share
the same E3 and target moiety. Thus, the features of the linker
(type, length, attachment position) can affect which surface
residues in the target protein might be involved in the complex
formation. Interestingly, the interprotein contacts, even though
having little contribution to the binding affinity of the interac-
tion, seem to be the main drivers of selectivity. The plasticity of
the binding and the distinct conformations of the degraders can
result in effective degradation even in the absence of tight
binding of the small molecule to the POI. In particular for rela-
tively short linkers, the conformational constraints give access to
only a few interprotein contact conformations and this feature
could be a driver of selectivity and at the same time improve the
drug-like properties of the degrader. In a study published earlier
this year by Smith et al. [55], isoform-selective p38-MAPK target-
ing PROTACs were designed by using only one warhead and one
E3 ligase. In all cases, the kinase inhibitor foretinib was used and
VHL inhibitors. The authors show that varying the linker length
and linker attachment point induced significant differences in
isoform selectivity (p38α or p38δ), even by adding only one extra
atom on the linker.
To date, there are limited examples of X-ray structures of
ternary complexes. Very recently Ciulli et al. solved high-
resolution ternary complex crystal structures and together
with biophysical data rationally optimized the structures
toward ACBI1 (18), a potent and cooperative degrader of
SMARCA2, SMARCA4 and PBRM1 [56].
Regarding the design of degraders, valuable structural informa-
tion is accumulating regarding the bindingmodes of the E3 ligase
ligands. In 2010, Ito et al. [12] identified the molecular target of
thalidomide as cereblon and in 2014, Hartmann et al. [57] showed
that thalidomide and its derivatives mimic uridine. The nature of
the binding pocket resembles an aromatic cage with three trypto-
phan residues. Thalidomide and its derivatives bind through the
glutarimide ring into the aromatic cage, while the rest of the
molecule protrudes from the binding pocket. More recently,
Boichenko et al. [58] investigated thoroughly the chemical ligand
spaceof cereblon, by solvingmultiple X-ray structures. Thebinding
Figure 3. (a)Stereo view of ligand – protein interactions between MZ1 (magenta sticks) with BRD4 (blue cartoon), pVHL (green cartoon): hydrogen bonds (red
dashes), cat_dip (magenta dashes), dipolar (cyan dashes), hdon_pi (yellow dashes), vdW (dark blue dashes), pi_pi (orange dashes). The key aminoacids participating
in the interactions are shown in sticks (b)Stereo view of protein – protein interactions between BRD4 (blue cartoon), pVHL (green cartoon):H bonds as red, ionic as
pink and van der Waals as yellow dashes. The key aminoacids participating in the interactions are shown in sticks. The figure was prepared by using Scorpion (Desert
Scientific Software, http://saas1.desertsci.com/) and Pymol (The PyMOL molecular graphics system, version 2.0 Schrödinger, LLC).
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of the compounds was determined by a FRET assay and terato-
genic effects were evaluated in a zebrafish model.
A pharmacophore model for binding to cereblon was established;
at least one carbonyl group of the glutarimide ring is necessary for
binding, whereas the second carbonyl increases the affinity for 5-
and 6-membered rings. In general, 5-membered rings showed
higher affinity than 6-membered, whereas 7-membered rings
didn’t show detectable binding. Moreover, 4-membered lactams
were comparable to 5-membered rings. The presence of
a heteroatom in the ring and the effect of substitutions were also
explored. In all cases, a non-substituted NH group in the ring is
crucial for binding. The structural data indicate the optimized
minimal binding moieties needed for cereblon binding and pro-
vide valuable insight for future cereblon effectors.Moreover, a new
co-crystal structure for the cereblon modulator (CC-885) (19),
which demonstrated antitumor effects through the recruitment
and degradation of G1 to S phase transition 1 protein (GSPT1), was
disclosed [59]. Furthermore, SARs of glutarimide analogues deriv-
ing from CC-885 were established for compounds that promote
thedegradationofAiolos and/orGSPT1 [60]. A cereblonmodulator
(CC-220) (20) showed improved cellular degradation of the tran-
scription factors Ikaros and Aiolos [61], which in this case derives
from improved affinity between the compound and cereblon. The
crystal structure of cereblon – CC-220 and DDB1 (Damage Specific
DNA Binding Protein 1) indicates that the increase in potency
correlates with increased contacts between CC-220 and cereblon,
away from themodeled binding site of Ikaros andAiolos (Figure 4).
Regarding inhibitors for the Von Hippel Lindau (VHL) E3
ubiquitin ligase, the group of Ciulli [62] has reported extensive
SARs and solved X-ray structures in an effort to optimize the
series. The best compounds show double-digit nanomolar
affinities for binding to VHL and improved cellular activity on
the VHL:HIF-1α-PPI (compounds (21), (22)). All known exam-
ples of VHL inhibitors contain the moiety of hydroxyproline
(Hyp), since VHL features a Hyp recognition site that targets
for degradation post-translationally hydroxylated HIF-1α sub-
units. Recently, Ciulli et al. [63] focused on novel fluorinated
hydroxyprolines (F-Hyps). A synthetic route was successfully
established for all four diastereoisomers of 3-fluoro-4-hydro-
xyprolines (F-Hyps) (23), followed by quantum mechanical
calculations, NMR spectroscopy and small-molecule X-ray crys-
tallography to delineate the effect of the fluorination on the
conformational preferences of the core. The fluorination of
Hyp had negligible effects on the hydrogen bond donor capa-
city of the C4 hydroxyl, however it actually led to the inversion
of the natural preference from C4-exo pucker to the C4-endo
Figure 4. (a) Chemical structures of CC-885 (19), CC-220 (20), compound 10 (21)and compound 15 (VH298) (22)and F-Hyps epimers (23), (b) Crystal structure of CC-
885 (purple sticks) with GSPT1 (light blue surface) and CRBN (magenta surface) [PDB 5HXB], (c) Crystal structure of CC-220 (purple sticks) with DDB1 (light blue
surface) and CRBN (red surface) [PDB 5V3O], (d) Crystal structure of compound 10 (magenta sticks) with pVHL:EloB:EloC (light blue surface) [PDB 5NVX], E) Crystal
structure of compound 15/VH298 (green sticks) with pVHL:EloB:EloC (light blue surface) [PDB 5LLI].The figure was prepared in Pymol (The PyMOL molecular graphics
system, version 2.0 Schrödinger, LLC).
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pucker. Despite this inversion, F-Hyps were still able to bind to
the VHL E3 ligase. The observed preferential recognition of the
(3R,4S) epimer of F-Hyp could be utilized for expanding the
chemical space of degraders. Moreover, despite a weakened
affinity, the (3S,4S)-F-Hyp that was incorporated in the
PROTAC MZ1 still led to Brd4-selective cellular degradation.
The same group utilized fragment-based screening and
computational methods for surface probing in order to iden-
tify ligandable pockets on the VHL E3 ligase [64]. Until
recently, only the HIF-recognition site was known as
a ligandable. Ciulli et al. identified two more ligandable sites
and reported crystal structures of the VHL: EloC: EloB E3
ubiquitin ligase with fragment-based hits. Two fragments
were bound to a small cavity at the EloC:Cul interface, whereas
one more fragment was bound in a cryptic pocket in VHL.
The accumulation of structural data, both for the E3 ligases
commonly targeted in proteolysis targeted chimeras, as well
as the crystal structures of the ternary complexes are expected
to significantly facilitate the design and optimization of the
degraders in the future.
3. Computational tools
Computational tools have already been applied in PROTAC design
in an effort to rationally design and optimize the different compo-
nents of the heterobifunctional molecule. A clear overview is
provided in the recent work of Drummond and Williams [65]. In
general, the multiple possible conformations and the observed
plasticity in the recently disclosed ternary complexes' X-ray struc-
tures show that there are still challenges to overcome. One of the
main concerns is the applicability of the computational
approaches in multiple targets, including different E3 ligases and
varying linkers that are known to have a significant impact on the
possible conformations. In their recent work, Drummond and
Williams [65], propose and validate four different methods for
generating in silico ternary complexes, covering different ways
for the preparation of PROTAC conformations. The one extreme
being the samplingof conformations separately from their binding
proteins and the other extreme that the whole ternary complex
being present during the sampling. In general, the protein-protein
docking-based method, in which PROTAC conformations were
sampled independently of the proteins, but protein-protein dock-
ing was included to provide possible ligase-target arrangements,
was considered superior andwas accurate enough to complement
structural optimization and provide crystal-like ternary complexes.
Even so, it is expected that the predictability and accuracy of
computational tools for PROTAC will keep evolving as more struc-
tural data become available.
4. Ternary complexes and kinetics
Regarding their mode of action, PROTACs differ significantly
from classical inhibitors. Until recently, the design of PROTACs
mostly considered the formation of the complex with the pro-
teins as two binary interactions, in which the two warheads were
optimized separately for individual interactions with the target
proteins. However, now it is unambiguously proven that the
linkers have a much more active role than keeping the ligands
in proximity and can greatly affect the degradation, as well as the
isoform specificity [53–55]. In contrast to a typical binary complex
that occurs during the interaction of an inhibitor with the target
protein, where the inhibitor is required to bind to a functional
binding site and block a single protein interaction, PROTACs
result in a ternary complex in which recognition is crucial,
whereas potency is of reduced significance [66]. There are three
different possibilities regarding the formation of ternary complex
and the subsequent effective degradation [67]. The first possibi-
lity for effective degradation to occur is via the formation of
a stable ternary complex, which requires high affinity between
the POI and the PROTAC, as well as favorable interactions with
the E3 ligase. In the second possibility, even with somehowweak
affinity, but with favorable interactions, degradation can be
effective if the ternary complex is stable. On the contrary, in the
third possibility, high affinity in the absence of favorable interac-
tions results in an unstable ternary complex and thus degrada-
tion is ineffective. Therefore, PROTACs are suitable for ‘difficult’
targets, where the known inhibitors are able to interact with the
target, but due to weak binding are unsuitable for further clinical
development or for protein – protein interactions where the
absence of well-defined pockets is a typical feature.
Regarding kinetics, PROTACs also differ from classical inhi-
bitors. In multiple studies with PROTACs, the ‘hook effect’ was
frequently observed when high concentrations were used. In
case of high concentrations, the binary complexes PROTAC: E3
ligase and PROTAC: POI are hindering the formation of the
ternary complex due to saturation, which is required for
degradation. Moreover, since there are two proteins involved
in the formation of the ternary complex, the binding affinity of
the PROTAC to one protein partner may be either enhanced or
reduced by the presence of the second protein. The quantifi-
cation of this effect, which is known as ‘cooperativity’ is pos-
sible by defining the ratio of binary and ternary dissociation
constants of PROTAC binding to the first protein [53,68].
Positive cooperativity implies that the ternary binding affinity
is enhanced compared to binary, whereas in negative coop-
erativity the ternary complex is destabilized. Neutral coopera-
tivity indicates that there is no change in the presence of
the second protein.
The understanding of these phenomena and the kinetic ana-
lysis of ternary complexes are crucial for further PROTAC optimiza-
tion and development. The applicability of biophysical techniques
(X-ray, NMR, ITC, AlphaLISA, TR-FRET) to study binary and ternary
complexes has been reviewed in detail by Ciulli et al. [66]. More
recently, the group of Ciulli [68] developed an SPR-based assay to
quantify the stability of PROTAC-induced ternary complexes and
to explore the kinetics equilibria between binary and ternary
complex formation as a quantitatively label-free technique.
In 2018, a modular live-cell platform utilizing endogenous
tagging was disclosed and applied to the monitoring of the
PROTAC-mediated degradation of bromodomains [69]. The
authors combine CRISPR/Cas9, endogenous tagging and lumi-
nescent technology in order to kinetically measure target
protein levels. Combination of this technology with optimized
bioluminescence resonance energy transfer (NanoBRET) was
applied to kinetic measurements of intracellular protein inter-
actions along the degradation pathway, including the ternary
complex formation, ubiquitination, and PROTAC-target
engagement. Overall, the technique allows for better
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understanding of the cellular mechanism of action and
assesses which stages of the degradation process are
impacted by the recruitment of different E3 ligase complexes.
5. Homo-PROTACs
Homo-PROTACs are a unique type of proteolysis-targeting chi-
meras comprised of two identical molecules linked together.
Homo-PROTACs were first reported for the VHL [70], based on
the structures of two potent VHL ligands (VH032 and VH298). The
linker was attached on different positions and the length of the
polyethylene glycol chains varied from 3 to 5 ethylene glycol
units. The biological evaluation of the homo-PROTACs revealed
that the most active compounds were selectively degrading the
long isoform of VHL. The position of the linker and the stereo-
chemistry were crucial for degradation. The trans epimer of Hyp
was required for degradation, as expected. Moreover, shorter
linker lengths led to decreased degradation. The most active
compound (CM11) (24) induced complete deletion of pVHL30
after 4 h at 10nM. In highmicromolar concentrations, the ‘hook –
effect’ was observed. A competition experiment confirmed that
the degradation activity was due to VHL binding. Furthermore,
isothermal titration calorimetry (ITC), size-exclusion chromato-
graphy (SEC) and AlphaLISA proximity assay were performed to
assess the formation of the ternary complex in solution. The
binding ratio of CM11 to VHL was proved to be 1:2, in contrast
to the 1:1 ratio observed for the inhibitor VH032. Overall, PROTAC
CM11 is described as a chemical probe for rapid and selective
pVHL30 knockdown, useful for further investigating the biologi-
cal function of pVHL.
In 2018, homobifunctional PROTACs that utilize cereblon
(CRBN) as the hijacked degrader and at the same time, as the
protein targeted for degradation, were described, aiming at
the chemical-induced CRBN degradation [71]. Two pomalido-
mide moieties were conjugated via linear linkers with varying
length, varying hydrophobicity, and different attachment posi-
tions. Western blot analysis was performed for the multiple
myeloma cell line MM1S, which expresses endogenous CRBN
and its immunomodulatory-induced (IMiD) neo-substrates
IKZF1, IKZF3, and casein kinase 1A1 (CK1α). All homo-
PROTACs in these series induced a dose-dependent decrease
in IKZF1 protein levels, however the impact on IKZF1 degrada-
tion varied. The compound with linker length of eight atoms
(CC15a) (25) was identified as the most potent CRBN degra-
der. In high concentrations, the ‘hook effect’ was observed.
Co-immunoprecipitation proved that the homo-PROTAC leads
to the formation of ternary complexes with 2:1 stoichiometry
with two CRBNs and one PROTAC molecule. The most active
PROTAC degraded specifically CRBN and showed only weak
effects on the neo-substrates, with no effect on other mem-
bers of the CRL3 ligase family (Figure 5).
In continuation of the homo-PROTAC approach, Ciulli et al. [72]
investigated the hypothesis that the E3 ligases themselves could
be hijacked against each other using a heterodimerizing PROTAC,
leading either to degradation of both E3 ligases or preferential
degradation of one E3 ligase. A library of CRBN – VHL PROTACs
was designed and synthesized, using pomalidomide as CRBN
handle and as for the VHL handle, structural modifications were
designed on two known VHL ligands, including different
attachment points of the linker. Three series of PROTACs were
designed and the degradation was studied by western blot ana-
lysis in HeLa cells, including the previously disclosed homo-
PROTACs CM11 and CC15a as positive controls for VHL and
CRBN degradation, respectively. A few compounds led to signifi-
cant degradation of CRBN, whereas none of the compounds
showed significant degradation of VHL. Testing the compounds
at low concentration to rule false-negative results due to the ‘hook
effect’, revealed that some compounds showed up to 50% degra-
dation of pVHL30. Thus, the concentration could affect the pre-
ferential degradation of one ligase over the other. Themost active
compound (PROTAC 14a)(26) was further studied in both HeLa
and HEK293 cells and induced CRBN degradation rapidly, with
high potency and to profound levels. In this ‘double-hijacking’
approach the VHL – CRBN PROTACs resulted in preferential degra-
dation of CRBN over VHL. Further mechanistic studies are
expected to illustrate the effect of the different elements that are
involved; the conjugation patterns, the linker lengths or the struc-
tures of the heterodimerizing PROTACs.
Moreover, Gütschow et al. [73] have also described eight VHL –
CRBN PROTACs and investigated the degradation on themyeloma
cell line MM1S. In most cases, CRBN levels were decreased,
whereas no reduction was observed for VHL protein levels. The
most active compound CRBN-6–5-5-VHL (27) showed
a negligible effect on the degradation of the neo-substrates
IKZF1 and IKZF3 and was superior compared to the homo-
PROTAC 15a. Regarding SAR, the linker length and the lipophilicity
were considered the crucial factors, whereas the polar surface area
was less significant. Overall, only CRBN was degraded by the
CRBN – VHL PROTACs. Such compounds have potential as chemi-
cal probes to elucidate ligand specificities, as well as potential
therapeutic value.
Wang et al. [74] reported MDM2 heterodimer PROTACs, by
linking the MDM2 inhibitor MI-1061 either with a CRBN ligand
or a VHL ligand. For MDM2 – CRBN PROTACs, SARs were
established regarding the length and the type of linker, mod-
ifications on the cereblon ligand and attachment point of the
linker. The most potent compound, MD-224 (28), was the
result of linker rigificiation; two methylene groups were con-
verted into an alkyne group and this significantly improved
the potency. The authors investigated also MDM2 – VHL
PROTACs with the MDM2 inhibitor MI-1061, however in all
cases MDM2 – VHL PROTACs were less potent than the corre-
sponding MDM2 inhibitor. Extensive mechanistic studies were
performed for MD-224. The compound was able to achieve
complete and durable tumor regression in the xenograft
tumor model in mice and was proven to be much more
efficacious than the MDM2 inhibitor MI-1061. Interestingly,
a ‘no-linker’ version was also active in degrading MDM2, how-
ever to a much lesser extent.
6. Tau-PROTACs
Tauopathies belong to neurodegenerative diseases, with char-
acteristic accumulation of aberrant forms of tau protein, which
results in neuronal death in focal brain areas. In particular for
Alzheimer’s disease (AD), although the exact pathogenesis
remains elusive, several hypotheses have been proposed, such
as chronic inflammation, oxidative stress, acetylcholine
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abnormalities, β-amyloid cascade, and pathogenic tau protein. In
2016, Li et al. [75] showed that multifunctional molecules, con-
sisting of a Tau-recognizing peptide moiety, a cell-penetrating
peptide, and an E3 ligase-recognizing peptide moiety, can
enhance Tau degradation in cells. The multifunctional peptides
were tested for their ability to induce Tau degradation in a stable
mouse neuroblastoma N2a-based cell line. The compound
TH006 appeared to be themost potent and it was further studied
in a fluorescence polarization assay. Confocal microscopy data
showed that TH006 was able to enter into cells and further
analysis by western blots and flow cytometry proved that it
induced effective intracellular tau degradation.
In 2018, Jiang et al. [76] reported a peptide PROTAC targeting
Tau by recruiting the Keap1 – Cul3 ubiquitin E3 ligase. The sub-
strate of the Keap1 – Cul3 ubiquitin E3 ligase is the transcription
factor NF-E2-related factor-2 (Nrf2), which is involved in the reg-
ulation of oxidative stress. The dysregulation of Keap1-Nrf2 signal-
ing is affecting both oxidative stress and inflammatory-related
diseases. The authors focused on peptide PROTACs, hijacking
the Keap1 and thus leading to ubiquitination and degradation of
Tau, as an alternative to inhibiting Nrf2. One of the peptide
PROTACs was able to interact effectively with Keap1 and Tau,
showed cell penetration and induced Tau degradation in different
cell lines overexpressing Tau. The data from this study clearly show
the potential of PROTAC degradation in neurodegenerative dis-
eases. Likely, however, peptide-based PROTACs and even small
molecule-based PROTACs will need considerable optimization to
pass the blood-brain-barrier.
Recently, an application of PROTAC combined with position
emission tomography (PET) tracers, which are useful tools for
Figure 5. (a) VHL HomoPROTAC, (b) CRBN HomoPROTAC, (c and d) CRBN – VHL PROTACs, (e) MDM2 – CRBN PROTAC, (f) Tau-CRBN PROTAC, (g) structures of
enzalutamide and ARCC PROTAC.
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the diagnosis of tauopathies, was reported [77]. The most
clinically advanced tau PET tracer (18F-T807 or 18F-AV-1451)
was coupled via linkers to pomalidomide. A library of 25
hetero-bifunctional molecules with various linker sizes and
attachment chemistry was synthesized. The lead PROTAC
QC-01–175 (29) was evaluated in a biolayer interferometry
(BLI) assay for degradation against the wild-type and the two
variant forms of recombinant human tau: A152T and P301L.
Although the PET tracer 18F-T807 shows off-target activity
against the monoamine oxidases A and B (MAO-A, MAO-B),
the off-target MAO binding was significantly reduced with the
PROTAC QC-01–175. Moreover, the PROTAC was evaluated in
a human neuronal cell model of tauopathy and promoted tau
clearance in a concentration-dependent manner, thus achiev-
ing the rescue of tau-mediated neuronal stress vulnerability. It
is noteworthy that the PROTAC had minimal effects on tau
from wild-type control neurons and targeted preferentially tau
species from FTD (frontotemporal dementia) neurons, expres-
sing tau-152T or tau-P301L, indicating specificity for disease-
relevant forms. The mechanism of action of QC-01–175 was
also investigated by targeting each component that is
expected to be involved in proteasomal degradation. The
data showed that the degradation depends on CRBN and
tau binding, as well as neddylation and proteasome function,
whereas autophagy is not involved. Further optimization of
the compound would be necessary for clinical development,
since it is a relatively large and flexible molecule and might
suffer from poor brain penetration or fast metabolism.
Although the PROTAC showed improved off-target effects in
the case of MAO-A and MAO-B, mass spectrometry global
proteome analysis showed that members of the C2H2 zinc
finger protein family were also downregulated, due to CRBN-
binding. Optimization to remove these IMiD off-target effects
would be necessary toward a more selective tau degrader.
Nevertheless, QC-01–175 will significantly contribute to stu-
dies in human tauopathies.
The PROTAC-mediated Tau degradation is also being con-
sidered for the Alzheimer’s disease treatment. In a recent
patent highlight [78], compounds with tau binding properties
were linked to thalidomide or lenalidomide with varying linker
length and composition. The ability of these compounds to
induce tau degradation was demonstrated in assays with
human cells. Further in vivo assays were performed and the
blood-brain barrier permeability was examined.
7. Toward clinical trials
PROTAC protein degraders entered the patent literature for
the first time by the biotech Proteinix in 1999 but they never
followed up with their patent [79]. Two years later, Craig
Crews from Yale University started publishing on targeted
degraders [1]. By 2008, Crews and coworkers reported the
first non-peptidic PROTACs, based entirely on small molecules
and degrading androgen-receptor (AR) by recruiting MDM2 as
the E3 ligase [40]. In 2013, Crews founded the biotechnology
start-up Arvinas (New Haven, CT) to develop PROTAC technol-
ogy to the clinic. In 2017, Arvinas selected AR PROTAC for
prostate cancer and estrogen-receptor (ER) PROTAC for breast
cancer as the first clinical trial candidates.
ARV-110 is the first PROTAC protein degrader which is clini-
cally evaluated by Arvinas. Currently, a phase 1 clinical trial is
ongoing with ARV-110 in patients with metastatic castration-
resistant prostate cancer (mCRPC) [NCT03888612, https://clinical
trials.gov/ct2/show/NCT03888612?spons=Arvinas&rank=1].
The structure of ARV-110 is not disclosed. ARV-110 is an
orally bioavailable AR PROTAC which shows consistent activity
and potency in various in vitro and in vivo systems and shows
efficacy in enzalutamide-resistant prostate cancer. ARV-110
degrades AR in all tested cell lines (for example LNCaP and
MCF7) with a half-maximal degradation concentration (DC50)
of ~1nM. AR degradation by ARV-110 leads to the suppression
of the AR-target gene PSA expression, inhibition of AR-
dependent cell proliferation and induction of potent apoptosis
in VCaP cells. DMPK and exploratory toxicology studies show
robust oral, dose-proportional drug exposure in rodent and
non-rodent species. In mouse models, ARV-110 degrades clini-
cally relevant mutant AR. It shows activity in a high androgen
environment. In mouse xenograft studies, more than 90% AR
degradation is observed at a 1 mg/kg PO QD dose. Significant
inhibition of tumor growth and AR signaling can be achieved
in both an intact and castrate setting. Further ARV-110
demonstrates in vivo efficacy and reduction of downstream
oncogenic Erg protein in a long term, castrate, enzalutamide-
resistant VCaP tumor model [80].
An interesting head-to-head comparison between enzaluta-
mide (30), and a similar PROTAC derivative to ARV-110, ARCC-4
(31), across different cellular models of prostate cancer drug
resistance, revealed ≥95% of cellular androgen receptor depletion,
inhibition of prostate tumor cell proliferation, degradation of clini-
cally relevant androgen receptor point mutants and unlike enza-
lutamide, retainment of antiproliferative effect in a high androgen
environment. Thus, AR PROTACs have the potential to overcome
drug resistance of direct AR inhibitors [81].
8. Conclusion
PROTACs are not following the classical drug discovery rules
and in a lot of aspects, such as the mechanism of action, the
kinetics, the formation of the ternary complex, the catalytic
mode-of-action, the obvious deviation from Lipinsky’s rule of
five, there is still a lot to be established. However, the first
crystal structures of ternary complexes, as well as kinetic
studies and biophysical assays have significantly improved
our understanding for this new modality. Impressive preclini-
cal data have been accumulated for numerous challenging
targets, including the Tau protein, the androgen, and the
estrogen receptor. Here, we provide an overview of the
types of degraders, examples of PROTACs for various targets,
a structural analysis based on crystal structures and aspects of
PROTACs kinetics. The special cases of homoPROTACs and tau-
PROTACs are analyzed further. Overall, PROTACs represent
a new modality with game-changing potential in drug
discovery.
9. Expert opinion
PROTACs differ significantly from small-molecule inhibitors
and in a lot of cases, unanticipated findings were revealed.
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For example, in 2018 [82], in the case of BET-VHL PROTACs, it
was proven that the most potent inhibitor does not necessa-
rily generate the most potent degrader. In the case of BCL6
[83], selective BCL6 inhibitors were developed and subse-
quently a BCL6-PROTAC, that even though was able to
degrade the target, failed to induce a significant phenotypic
response, despite achieving cellular concentrations. The latter
was the consequence of a residual undegradable BCL6 popu-
lation. On the contrary, in some cases, such as the targeting of
focal adhesion kinase (Fak) [84], where kinase inhibitors have
a low success rate in clinical trials, the optimized clinical
candidate defactinib was outperformed by the designed
PROTAC. PROTACs, apart from applications in difficult or
undruggable targets, could also be a suitable strategy to over-
come resistance. In the case of Bruton’s tyrosine kinase (BTK)
in chronic lymphocytic leukemia (CLL), resistance can occur
after the mutation of a cysteine to a serine. Therefore, the
irreversible covalent inhibitor ibrutinib is unable to bind to the
target. In an interesting approach [25] ibrutinib was converted
into a PROTAC, by removing the covalent warhead and was
able to even degrade the mutated target, in contrast to the
inhibitor. It is noteworthy, that very recently it was shown [85]
that resistance in cancer cell lines following chronic PROTAC
treatment can occur. In this study, resistance was observed
both for VHL- and CRBN-based BET PROTACs, as a result of
genomic alterations that compromised core components of
the E3 ligase complexes. On the contrary, secondary mutations
affecting the compound binding to the target were not
observed. It should be noted that the observed resistance
was specific for the individual PROTAC, meaning that cells
that became resistant to the VHL-recruiting PROTAC remained
sensitive to CRBN-based PROTAC and vice versa.
The application of PROTACs against numerous targets and
the impressive responses clearly show that they are a powerful
new modality. However, they are still aspects that are not fully
elucidated. Therefore, the accumulation of more structural
data regarding the ternary complex and the different steps
involved in the degradation process would significantly facil-
itate the rational design of PROTACs as well as the optimiza-
tion of the crucial components.
Moreover, PROTACs are mostly described for four members
of the E3 ligase family. However, in humans, there are more
than 600 of them. So far, only a very limited part of them has
been utilized and the choice of the E3 ligase to target is not
always rational. Studies exploring the different E3 ligases sui-
table for PROTACs are still underdeveloped. This would require
the detailed structural analysis of the ligases, their recognition
requirements, and their druggability. A recent example in this
direction focused on the structural basis for recruitment of
DAPK1 to the KLHL20 E3 ligase and the possibility of using
this E3 ligase in PROTACs [86]. Moreover, PROTACs are usually
designed having as starting point a known, potent ligand for
the protein of interest, which is appropriately modified in
order to attach the linker and at the same time maintain the
features necessary for binding. This is an important limitation,
in cases of protein – protein interactions, where there might
be lack of small molecules or absence of exact structural data
to guide the modification of the structure. Better understand-
ing of the recognition phenomena of PROTACs would be
necessary to be able – ideally – to design PROTACs even for
targets lacking known inhibitors.
Selectivity so far has proven to be a great advantage of
PROTACs, including isoform selectivity [53–55] and the use of
non-selective inhibitors that can be converted into selective
PROTACs [53]. However, regarding the underlying biology for
the E3 ligases aspect, there are still missing data. In particular
for IMiDs that bind to cereblon, the neo-substrates include
seemingly unrelated proteins (IKZF1, IKZF3, CK1α and GSPT1).
IKZF1 and IKZF3 belong to C2H2 zinc finger proteins, which
are the largest class of putative transcription factors in the
human proteome with approximately 800 members. It was
shown recently, that IMiDs indeed are capable of inducing
the degradation of a large number of proteins through
a C2H2 degron [87]. On the one hand, this observation indi-
cates the potential of CRBN-binding small molecules in target-
ing transcription factors, but on the other hand raises the
question of possible off-target effects deriving from PROTAC-
mediated degradation of the C2H2 zinc finger proteins.
With the first PROTACs reaching clinical trials, the results
are greatly anticipated to establish their clinical significance.
Evidence of their long-term effects or potent toxicity is still
missing.
In comparison to other promising techniques, such as CRISPR
and RNAi for cancer treatment, PROTACs have the advantage of
a catalytic mechanism of action and the reversible binding to the
target. The effect is not permanent, thus in contrast to CRISPR,
fewer off-target effects are anticipated [88]. It is expected that
the highly anticipated clinical data for those techniques will
further elucidate their strengths and limitations.
PROTACs are relying on the ubiquitin proteasome system to
degrade intracellular targets. A novel expansion to the field of
targeted protein degradation, which shows the tremendous
potential of this approach, is the heterodimeric molecules called
ENDTAC (endosome targeting chimera) [89]. In this very first
report, Crews et al. show that extracellular targets can be inter-
nalized and degraded via the receptor – mediated endolysosomal
pathway. The approach was applied to an extracellular recombi-
nant fusion protein, which was internalized and degraded by
hijacking the decoy GPCR receptor, CXCR7. This method could
potentially overcome the limitation of intracellular protein target-
ing by PROTACs and could be applied to secreted, extracellular
proteins. Overall, the degradation of protein targets is a highly
exciting field and will likely revolutionize drug discovery.
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